Wockhardt (NSE:WOCKPHARMA) E10: ₹-14.83 (As of Mar. 2026)


NSE:WOCKPHARMA Wockhardt Ltd NSE:WOCKPHARMA
66 GF Score
Price ₹1,810.70
GF Value ₹1,267.68
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Wockhardt E10?

Wockhardt NSE:WOCKPHARMA -1.12% 66 E10 is ₹-14.83 as of Mar. 2026. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 66/100 and a GF Value™ of ₹1,267.68 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Wockhardt's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹10.220. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹-14.83 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Wockhardt was -35.60% per year. The lowest was -35.60% per year. And the median was -35.60% per year.

As of today (2026-07-12), Wockhardt's current stock price is ₹1810.70. Wockhardt's E10 for the quarter that ended in Mar. 2026 was ₹-14.83. Wockhardt's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Wockhardt was 756.96. The lowest was 5.49. And the median was 11.59.


Wockhardt  (NSE:WOCKPHARMA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Wockhardt was 756.96. The lowest was 5.49. And the median was 11.59.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Wockhardt E10 Related Terms


Wockhardt E10 Historical Data

* Premium members only.

The historical data trend for Wockhardt's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wockhardt E10 Chart

Wockhardt Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.69 8.29 -6.32 -12.27 -14.83

Wockhardt Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.27 -14.22 -15.19 -15.85 -14.83

NSE:WOCKPHARMA vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wockhardt Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Wockhardt's Shiller PE Ratio falls into.


NSE:WOCKPHARMA
66GF Score
Wockhardt Ltd NSE:WOCKPHARMA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wockhardt E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Wockhardt's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=10.22/164.2724*164.2724
=10.220

Current CPI (Mar. 2026) = 164.2724.

Wockhardt Quarterly Data

per share eps CPI Adj_EPS
201606 1.318 105.961 2.043
201609 1.410 105.961 2.186
201612 -4.497 105.196 -7.022
201703 -14.569 105.196 -22.751
201706 -34.760 107.109 -53.311
201709 -0.276 109.021 -0.416
201712 -3.400 109.404 -5.105
201803 -12.874 109.786 -19.263
201806 -7.179 111.317 -10.594
201809 -1.898 115.142 -2.708
201812 -5.916 115.142 -8.440
201903 -1.207 118.202 -1.677
201906 -3.741 120.880 -5.084
201909 -6.838 123.175 -9.120
201912 0.802 126.235 1.044
202003 4.018 124.705 5.293
202006 63.004 127.000 81.494
202009 0.295 130.118 0.372
202012 1.262 130.889 1.584
202103 -7.701 131.771 -9.600
202106 -1.050 134.084 -1.286
202109 2.790 135.847 3.374
202112 0.560 138.161 0.666
202203 -18.187 138.822 -21.521
202206 -4.640 142.347 -5.355
202209 -13.150 144.661 -14.933
202212 -6.620 145.763 -7.461
202303 -14.370 146.865 -16.073
202306 -9.280 150.280 -10.144
202309 -5.370 151.492 -5.823
202312 -5.750 152.924 -6.177
202403 -11.650 153.035 -12.506
202406 -0.950 155.789 -1.002
202409 -1.470 157.882 -1.529
202412 0.910 158.323 0.944
202503 -1.570 157.552 -1.637
202506 -5.530 159.755 -5.686
202509 4.810 162.289 4.869
202512 3.610 163.281 3.632
202603 10.220 164.272 10.220

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹-14.83 mean?
Wockhardt (NSE:WOCKPHARMA) has a E10 of ₹-14.83 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Wockhardt and its competitors.
Is Wockhardt's E10 too high?
Wockhardt's current E10 is ₹-14.83. Overall, Wockhardt has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's E10 compare to ZTS and UTHR?
Wockhardt's E10 of ₹-14.83 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Wockhardt and its competitors. Wockhardt's current E10 is ₹-14.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,267.68, compared to a current price of ₹1,810.70 — trading 42.8% above its estimated fair value. The current E10 is ₹-14.83. Wockhardt's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current E10 is ₹-14.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued. The current stock price of ₹1,810.70 is trading 42.8% above its estimated GF Value™ of ₹1,267.68. GuruFocus considers Wockhardt to be Significantly Overvalued.

Key valuation signals for NSE:WOCKPHARMA:

  • E10: ₹-14.83
  • GF Value™: ₹1,267.68 vs. price of ₹1,810.70 (42.8% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wockhardt Business Description

Other Exchanges 532300:India
Address Bandra-Kurla Complex, Wockhardt Towers, Bandra East, Mumbai, MH, IND, 400051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
66GF Score

Get the complete analysis for NSE:WOCKPHARMA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,810.70
Price
₹1,267.68
GF Value